1. Home
  2. RIGL vs ZH Comparison

RIGL vs ZH Comparison

Compare RIGL & ZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • ZH
  • Stock Information
  • Founded
  • RIGL 1996
  • ZH 2011
  • Country
  • RIGL United States
  • ZH China
  • Employees
  • RIGL N/A
  • ZH N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • ZH Business Services
  • Sector
  • RIGL Health Care
  • ZH Consumer Discretionary
  • Exchange
  • RIGL Nasdaq
  • ZH Nasdaq
  • Market Cap
  • RIGL 335.5M
  • ZH 365.1M
  • IPO Year
  • RIGL 2000
  • ZH 2021
  • Fundamental
  • Price
  • RIGL $38.85
  • ZH $4.81
  • Analyst Decision
  • RIGL Buy
  • ZH Strong Buy
  • Analyst Count
  • RIGL 5
  • ZH 1
  • Target Price
  • RIGL $38.20
  • ZH $4.70
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • ZH 390.5K
  • Earning Date
  • RIGL 08-05-2025
  • ZH 08-27-2025
  • Dividend Yield
  • RIGL N/A
  • ZH N/A
  • EPS Growth
  • RIGL N/A
  • ZH N/A
  • EPS
  • RIGL 5.43
  • ZH 0.22
  • Revenue
  • RIGL $267,921,000.00
  • ZH $439,821,184.00
  • Revenue This Year
  • RIGL $59.93
  • ZH N/A
  • Revenue Next Year
  • RIGL N/A
  • ZH $7.46
  • P/E Ratio
  • RIGL $7.15
  • ZH $21.62
  • Revenue Growth
  • RIGL 105.62
  • ZH N/A
  • 52 Week Low
  • RIGL $12.66
  • ZH $3.13
  • 52 Week High
  • RIGL $43.72
  • ZH $6.32
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • ZH 56.37
  • Support Level
  • RIGL $39.00
  • ZH $4.58
  • Resistance Level
  • RIGL $42.08
  • ZH $5.01
  • Average True Range (ATR)
  • RIGL 2.32
  • ZH 0.28
  • MACD
  • RIGL -0.37
  • ZH 0.02
  • Stochastic Oscillator
  • RIGL 53.26
  • ZH 55.91

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About ZH Zhihu Inc. (every two of each representing one ordinary share)

Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.

Share on Social Networks: